Pharmaceuticals
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from bothChina's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). * EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is devel...
2025-10-13 08:47
2135
Reach Surgical's OMNIBOT Performs First Urology Robotic Telesurgeries in Latin America
Advancing regional collaboration and surgeon training in remote robotic-assisted surgery SINGAPORE, Oct. 13, 2025 /PRNewswire/ -- Reach Surgical, the Surgical Solutions division of Genesis MedTech, has facilitated the completion of two robotic telesurgeries using its OMNIBOT robotic-assisted sys...
2025-10-13 08:00
2029
Health in Your Hands? Asia's Top Health Experts Say 'Yes' and Reveal How
* Over 100 healthcare leaders from 11 countries/regions convene at APSMI Summit to advance consumer-led self-care in healthcare. * The Summit highlights the importance of empowering individuals with knowledge and tools to support resilient health systems. BALI, Indonesia, Oct. 10, 2025 /PRNew...
2025-10-10 14:43
2160
IHH Healthcare launches Global Incubator to fuel game-changing innovation
By enabling early-stage start-ups to bring breakthrough ideas to life, IHH is catalysing next-level care and driving lasting impact across the healthcare ecosystem. "Through this Global Incubator Programme, we are expanding our innovation drive to support early-stage healthcare innovators, empow...
2025-10-10 13:09
1991
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
* The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission * World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperati...
2025-10-09 20:50
6628
Chance Pharma Announces Commercialization Agreement with Huadong Medicine for Innovative Respiratory Drug CXG87
HANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement wit...
2025-10-09 17:27
2399
Herbalgy, the Pain Management Expert, Partners with Heroes in White to Champion a "Pain-Relieving Serenity" Lifestyle
Bringing the Wisdom of Traditional Chinese Medicine into Modern Living HONG KONG, Oct. 9, 2025 /PRNewswire/ -- Following the phenomenal success of TVB's widely acclaimed TV dramaHeroes in White—the top-rated series of 2025 with an audience of over 1.57 million and a rating of 24.2 points—Herbalgy...
2025-10-09 14:18
1923
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted acrossAsia. The study included a 12-week induction phase followed by a 40-week maintenance phase and represents the large...
2025-10-09 13:10
2074
New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific
* 32 million people in Asia-Pacific live with heart failure, and this number is rising fast. * New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years. * Urgent call for early diagnosis, digital and community-based care, and sustainable financing t...
2025-10-08 09:00
2314
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
* Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 2025 1-3 * MSA is a rare, rapidly progressing, neurodegenerative disease...
2025-10-02 16:41
2045
Major Health Management Wins the 2025 Health Brand Awards - Excellence Award in Health Technology (Health Examination Platform): 38 Years of Quality Commitment, Transforming into a Leading Health Technology Pioneer
TAIPEI, Oct. 1, 2025 /PRNewswire/ -- Taiwan's leading health management brand, Major Health Management, has been honored with the Excellence Award in Health Technology – Health Examination Platform at the 2025 Health Brand Awards. This award is a highly regarded annual recognition in the health i...
2025-10-01 14:51
2480
Telix Announces Record-Breaking Presence at EANM 2025
MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (E...
2025-10-01 13:57
2797
Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol
* Local survey reveals critical misconceptions and gaps in blood cholesterol management among people living inSingapore. * Almost one in three deaths in Singapore is attributed to cardiovascular disease, underscoring the urgent need to improve blood cholesterol management. [1] * Beat the Blo...
2025-09-30 10:00
1684
Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams
New IBD research shows that, even during clinical remission, people living with Crohn's diseasecontinue to experience greater work impairment than the general population The new campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endo...
2025-09-30 10:00
3119
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
* HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("...
2025-09-29 20:48
2072
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition...
2025-09-29 12:58
2947
Tourism Malaysia and MHTC Bring Malaysia Fair 2025 to Surabaya A Celebration of Culture, Cuisine, Travel, and Healthcare Excellence
SURABAYA, Indonesia, Sept. 26, 2025 /PRNewswire/ -- Tourism Malaysia, in collaboration with the Malaysia Healthcare Travel Council (MHTC), proudly presents Malaysia Fair 2025—a four-day celebration ofMalaysia's culture, cuisine, tourism, and healthcare excellence. Taking place at Pakuwon Mall, Su...
2025-09-26 09:45
4087
ADVANCION PUBLISHES 2024 CORPORATE SUSTAINABILITY REPORT
Fourth annual report highlights continued progress in sustainable innovation, safety, and responsible resource stewardship BUFFALO GROVE, Ill., Sept. 25, 2025 /PRNewswire/ -- Advancion Corporation ("Advancion" or "Company"), a global leader in life science buffers and proprietary specialty ingre...
2025-09-25 02:40
2661
The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)
* Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2 * Elevated lipoprotein(a) or Lp(a), an inherited condition that raises CVD risk, affects 1 in 5 people worldwide but is rarely tested3 * New survey across Asia Pacific and Middle East s...
2025-09-24 20:21
2467
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Glenmark Specialty S.A. (GSSA), a whol...
2025-09-24 19:45
3292
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 313 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
Most Read
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
10911
